Law Firm Offers Leadership Opportunity in Capricor Therapeutics Securities Case

Investors Take Note: Capricor Therapeutics Securities Fraud Lawsuit

The Rosen Law Firm, a leading player in global investor rights, has reminded shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) about the upcoming September 15, 2025, deadline for potential lead plaintiffs in a significant securities fraud lawsuit. This class action will cover securities purchases made between October 9, 2024, and July 10, 2025, inclusive of both dates.

If you purchased Capricor securities during this period, you might be entitled to compensation at no upfront cost, thanks to the firm's contingency fee agreement. Interested investors can join the class action by visiting the Rosen Legal website or contacting attorney Phillip Kim for more information.

What You Need to Know

The lead plaintiff designation is critical, as it allows an individual to act on behalf of all members in directing the case. Meanwhile, potential claimants are urged to ensure they choose experienced legal counsel. The Rosen Law Firm has a stellar track record, including the largest-ever securities class action settlement involving a Chinese company back in 2017.

The firm has consistently been recognized for its accomplishments in achieving settlements, which add up to hundreds of millions of dollars for investors over the years. With a reputation bolstered by accolades from established platforms like Lawdragon and Super Lawyers, Rosen Law Firm stands out as an advocate for shareholders.

Details Surrounding the Lawsuit

The lawsuit revolves around allegations that Capricor provided misleading information regarding its leading cell therapy candidate, deramiocel, intended for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Assertions regarding the company’s ability to secure a Biologics License Application (BLA) from the U.S. Food and Drug Administration (FDA) were notably positive.

However, reports reveal that Capricor concealed critical data about the safety and efficacy of deramiocel, particularly concerning the Phase 2 HOPE-2 trial results. As a result, investors were driven to buy Capricor’s securities at artificially higher prices. Once the true details about the safety and effectiveness of the treatment were revealed, it impacted the stock price adversely, leading to significant financial losses for many.

Next Steps for Investors

Interested shareholders should act quickly to secure their place in this class action. Although no class has been certified yet, participating now positions investors for any future recovery. Keep in mind that representation is not guaranteed until a class is certified, and potential claimants have the option to select their own counsel if they choose.

To participate, visit Rosen Legal or reach out to Phillip Kim at 866-767-3653. Follow Rosen Law Firm on LinkedIn, Twitter, or Facebook for continuous updates on this and other legal matters.

Attorney Advertising: Past results do not guarantee future outcomes.

This lawsuit poses a critical opportunity for all investors who have been impacted by the recent disclosures surrounding Capricor Therapeutics. With effective legal representation from a firm with proven success, shareholders may gain significant recourse against any losses incurred.

Stay alert, informed, and ready to act as this case develops further.